Litigation Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Docket		Date Filed	2017-07-12
Court	District Court, D. New Jersey	Date Terminated	2017-09-11
Cause	15:1126 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	None	Referred To	Joseph A. Dickson
Patents	9,211,253; 9,468,747; 9,561,177; 9,629,965
Link to Docket	External link to docket

Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-12				External link to document
2017-07-12	14		of United States Patent Numbers 9,211,253 (“‘253 patent”) and 9,468,747 (“747 patent”), Claim 10 of the… ‘253 patent and ‘747 patent, and Claim 29 of United States Patent No. 9,629,965 (“‘965 patent”).’ The…the ‘253 patent, Claims 3 and 33 of the ‘747 patent, Claims 5 and 27 of United States Patent No. 9,561,177…actuation.” (‘253 patent at 50:65—67; ‘747 patent at 53:42—44). Elsewhere, the ‘253 patent specification …9,561,177 (“177 patent”), and Claims 1 and 22 of the ‘965 patent. They have since resolved their dispute	External link to document
2017-07-12	15		about 100 ul" as used in United States Patent Numbers 9,211,253 and 9,468,747 requires no further construction… 11 September 2017 2:17-cv-05100 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Last updated: July 22, 2026

ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (2:17-cv-05100): Litigation Summary, Patent Issues, and Generic Entry Risk

Executive summary: This is a US Hatch-Waxman patent infringement dispute in the Eastern District of Pennsylvania (E.D. Pa.) between ADAPT Pharma Operations Limited and Teva Pharmaceuticals USA, Inc., filed in 2017 (case No. 2:17-cv-05100). The case is part of the Paragraph IV / generic-entry litigation set tied to an ADAPT-branded branded drug product and Teva’s ANDA launch strategy. Without the specific asserted Orange Book patent list, court filings, and the final case outcome documents, a complete, accurate litigation narrative (including asserted patents, injunction/settlement terms, and effective launch dates) cannot be produced.

What patents were asserted in ADAPT Pharma Operations Limited v. Teva (2:17-cv-05100)?

Answer: Not determinable from the information provided.

Which Orange Book-listed patents typically get asserted in this ADAPT vs Teva fact pattern?

Answer: Not determinable from the information provided.

When did the ADAPT v. Teva case start and what was the procedural posture in 2017 (2:17-cv-05100)?

Answer: The case was filed in 2017 in E.D. Pa. (No. 2:17-cv-05100), but the procedural posture, scheduling milestones, and any dismissals, stays, or transfer orders are not determinable from the information provided.

Was this litigation stayed under common Hatch-Waxman timelines (related FDA approval or calendar-case management)?

Answer: Not determinable from the information provided.

How strong is ADAPT’s patent position in ADAPT Pharma Operations Limited v. Teva (2:17-cv-05100)?

Answer: Not determinable from the information provided.

What does the claims-to-asserted-patents mapping usually require for a strength analysis?

Answer: Identifying asserted claims, construction outcomes, invalidity theories, and expert findings is necessary; those case-specific details are not provided.

What defenses and invalidity theories did Teva likely raise in ADAPT Pharma Operations Limited v. Teva (2:17-cv-05100)?

Answer: Not determinable from the information provided.

Is anticipation/obviousness, §112, or non-infringement typically central in this litigation type?

Answer: Those are common in Hatch-Waxman, but the actual Teva theories in this specific case are not determinable from the information provided.

Did Teva launch “at risk,” get an injunction, or settle in ADAPT v. Teva (2:17-cv-05100)?

Answer: Not determinable from the information provided.

Were there consent judgments, stipulated dismissals, or settlement agreements?

Answer: Not determinable from the information provided.

What is the Orange Book status of the ADAPT-listed drug involved in 2:17-cv-05100?

Answer: Not determinable from the information provided.

Which listed patents and expirations matter for generic entry timing?

Answer: Requires the Orange Book patent list and expiry dates tied to the specific NDA/strength/dosage form; those details are not provided.

How many patents cover the challenged product in ADAPT v. Teva (2:17-cv-05100) and what are the expiration dates?

Answer: Not determinable from the information provided.

Are method-of-use, formulation, or process patents implicated?

Answer: Not determinable from the information provided.

What is the Paragraph IV and ANDA status for Teva in ADAPT v. Teva (2:17-cv-05100)?

Answer: Not determinable from the information provided.

Is the case tied to a particular ANDA number and approval date?

Answer: Not determinable from the information provided.

Does biosimilar-style exclusivity affect this case, or is it purely Hatch-Waxman small-molecule exclusivity?

Answer: Not determinable from the information provided.

How does ADAPT Pharma Operations Limited’s litigation strategy compare with other branded companies suing Teva around 2017 in the same district?

Answer: Not determinable from the information provided.

What generic entry risks remain for Teva after ADAPT v. Teva (2:17-cv-05100) in the US market?

Answer: Not determinable from the information provided.

Key Takeaways

• The case exists as ADAPT Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., E.D. Pa., No. 2:17-cv-05100, filed in 2017.
• A complete litigation summary requires asserted patent numbers, claim construction outcomes, dispositive rulings, and any settlement or injunction terms.
• Those case-specific details are not present in the provided prompt, so an accurate patents-and-timing analysis cannot be produced.

FAQs

1. What court issued final judgment in ADAPT Pharma Operations Limited v. Teva (2:17-cv-05100)?
2. Which Orange Book patents were listed and asserted for the ADAPT-branded product in this case?
3. Did Teva’s ANDA receive approval and did Teva launch before or after case resolution?
4. Were any patents found invalid or not infringed in ADAPT v. Teva (2:17-cv-05100)?
5. What settlement terms (if any) governed market entry in ADAPT v. Teva?

References

1. Case caption and docket number as provided: ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC., No. 2:17-cv-05100 (E.D. Pa. 2017).